Here, you'll find clear definitions, explanations, and a sprinkle of wit to make understanding these conditions a bit less daunting and a lot more relatable
Under the arrangement, the defendant agreed to manufacture Semaglutide (Oral Tablet) 3 mg, 7 mg and 14 mg under the brand names Semalix and Sembolic comprising SNAC at 0.53 mmol and that it would not breach the range of 0.6 to 2.1 mmol claimed under the claim 1 of the plaintiffs' patent IN325669
doi: 10.18632/oncotarget.8604
BPC-157 acts primarily through VEGF/angiogenesis and gut-lining signalling pathways
The defendants motion to dismiss is scheduled for argument on August 1, 2025
Reddys, Zydus, Lupin and Alkem are among the local manufacturers that outlined plans to launch generic versions of Semaglutide in India, which has an estimated more than 10 crore adults living with diabetes, the second-highest number globally after China